DataSheet1_Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia.docx

DataSheet1_Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia.docx

Background<p>Methotrexate (MTX) is the primary drug used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, some patients exhibit delayed clearance of high-dose (HD) MTX, which induces severe nephrotoxicity, mucositis, hepatotoxicity, and neurotoxicity. We sought to ide...

Full description

Saved in:
Bibliographic Details
Main Author: Jung Yoon Choi (4725963) (author)
Other Authors: Hoshik Kwon (20202441) (author), Hyery Kim (306120) (author), Kyung Taek Hong (4725960) (author), Youngeun Ma (7901246) (author), Kyung-Nam Koh (10104716) (author), Sunmin Yun (6822512) (author), Keon Hee Yoo (7901249) (author), Sang Hoon Song (3937031) (author), Ho Joon Im (6822521) (author), Ju Han Kim (10092) (author), Hyoung Jin Kang (6822524) (author)
Published: 2024
Subjects:
Pharmacology
Basic Pharmacology
Clinical Pharmacology and Therapeutics
Clinical Pharmacy and Pharmacy Practice
Pharmaceutical Sciences
Pharmacogenomics
Toxicology (incl. Clinical Toxicology)
Pharmacology and Pharmaceutical Sciences not elsewhere classified
methotrexate
children
acute lymphoblastic leukemia
pediatric
pharmacogenomics
adverse reactions
delayed clearance
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items